ReviewMedical oncology (Northwood, London, England)2022
Addressing artifacts of colorimetric anticancer assays for plant-based drug development.
Review in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Electrochemical sensing of cell viability: A scalable platform from 2D monolayers to 3D tissue models.iScience · 2026Article
- Functionalized Core/Shell Gold-Palladium Bimetallic Nanoparticles in Transferrin-Targeted Dual-Drug Delivery in a Cervical Cancer Cell Model.Pharmaceuticals (Basel, Switzerland) · 2025Article
- In vitro and in vivo evaluation of the leishmanicidal and cytotoxic activities of chitosan and chitosan-amphotericin B.AMB Express · 2025Article
- Morphological Characterization, Polyphenolic Profile, and Bioactive Properties ofBiomolecules · 2024Article
- Green synthesis of silver nanoparticle prepared with Ocimum species and assessment of anticancer potential.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has become the silent killer in less-developed countries and the most significant cause of morbidity worldwide. The accessible and frequently used treatments include surgery, radiotherapy, chemotherapy, and immunotherapy. Chemotherapeutic drugs traditionally involve using plant-based medications either in the form of isolated compounds or as scaffolds for synthetic drugs. To launch a drug in the market, it has to pass through several intricate steps. The multidrug resistance in cancers calls for novel drug discovery and development. Every year anticancer potential of several plant-based compounds and extracts is reported but only a few advances to clinical trials. The false-positive or negative results impact the progress of the cell-based anticancer assays. There are several cell-based assays but the widely used include MTT, MTS, and XTT. In this article, we have discussed various pitfalls and workable solutions.
Indexed as
Identifiers
36071299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.